IMGN853

May 22, 2019

Mirvetuximab Combos for Platinum-resistant Ovarian Cancer Showing Promise in Trial Updates

News

Combining Immunogen‘s mirvetuximab soravtansine, an investigational antibody-drug conjugate, with Avastin (bevacizumab) showed signs of favorable efficacy and demonstrated a manageable safety profile in patients with platinum-resistant ovarian cancer, according to ... Read more

May 7, 2018

Phase 3 Trial of Mirvetuximab Soravtansine in Ovarian Cancer OK’d to Continue as Planned

News

A Phase 3 trial evaluating ImmunoGen’s mirvetuximab soravtansine (IMGN853) in platinum-resistant ovarian cancer patients is on its way to achieving its objectives, an interim futility analysis shows. As a result, the FORWARD ... Read more

May 22, 2017

ImmunoGen’s Investigative Therapy for Ovarian Cancer Shows Potential in Clinical Studies

News

ImmunoGen will show promising safety and efficacy data of its investigative treatment mirvetuximab soravtansine for the treatment of FRα-positive epithelial ovarian cancer (EOC). The positive top-line data will be presented in three poster ... Read more

May 8, 2017

Phase 1 Trial of Ovarian Cancer Therapy Mirvetuximab Supports Phase 3 Study

News

Results from a Phase 1 clinical trial of mirvetuximab soravtansine (IMGN853) as a treatment for chemotherapy-resistant ovarian cancer and other malignancies have propelled the therapy into a Phase 3 trial. ... Read more